1 in 10 US Adults Face Deadly Liver Disease Risk From Drinking and Obesity
New research finds heavy drinking plus obesity synergistically drive liver disease โ and GLP-1 drugs may treat both at once.
802 articles
New research finds heavy drinking plus obesity synergistically drive liver disease โ and GLP-1 drugs may treat both at once.
A once-undruggable cancer target may finally be cracked, with new data on daraxonrasib offering hope for pancreatic cancer patients.
A small but striking trial shows CAR-T immunotherapy eliminated all detectable myeloma cells in high-risk pre-cancer patients, prompting talk of cure.
New research links chronic low-grade inflammation to faster epigenetic aging, measured across four validated biological clocks.
A 12-week study found Omada's wraparound GLP-1 program doubled fat loss and nearly tripled muscle preservation vs. controls.
Seragon's SRN-901 outperformed rapamycin in aged mice, boosting median lifespan 33% and reducing frailty and tumor incidence.
Osteoboost raises $8M to scale a prescription vibration device shown to slow bone density loss in the 44M Americans with low bone density.
Recent NIA findings spotlight lifestyle factors cutting Alzheimer's risk by 60%, calorie restriction slowing aging, and a gene regulating plaque toxicity.
From an $80M genetics study to a single-injection heart therapy, new research is redefining what drives exceptional human lifespan.
Early data suggests the latest KRAS-targeting drugs outperform their predecessors in lung cancer treatment, marking a potential breakthrough.
A new drug targeting the KRAS mutation is transforming outcomes for pancreatic cancer patients, potentially opening doors for other cancers.
New genetic and proteomic findings from centenarian studies uncover biological markers that distinguish the longest-lived humans from the rest of us.